Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Navidea Biopharmaceuticals Inc NAVB

Healthcare Biotechnology
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on... see more

Recent & Breaking News (GREY:NAVB)

Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition

Business Wire December 9, 2021

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

Business Wire November 10, 2021

Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update

Business Wire November 3, 2021

Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin

Business Wire October 26, 2021

Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors

Business Wire October 14, 2021

Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer

Business Wire September 27, 2021

Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition

Business Wire September 17, 2021

Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results

Business Wire August 11, 2021

Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update

Business Wire August 4, 2021

Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications

Business Wire July 19, 2021

Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis

Business Wire July 15, 2021

Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty

Business Wire June 24, 2021

Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections

Business Wire May 19, 2021

Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results

Business Wire May 11, 2021

Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent

Business Wire May 11, 2021

Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition

Business Wire May 5, 2021

Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update

Business Wire May 4, 2021

Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium

Business Wire April 15, 2021

Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

Business Wire March 24, 2021

Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update

Business Wire March 17, 2021